第 4 周的血浆利巴韦林谷浓度可预测接受慢性丙型肝炎治疗的 HIV/HCV 合并感染患者的丙型肝炎病毒（HCV）复发。
Plasma ribavirin trough concentrations at week 4 predict hepatitis C virus (HCV) relapse in HIV-HCV-coinfected patients treated for chronic hepatitis C.
机构信息
Laboratory of Pharmacology, Hospital Carlos III, 28029 Madrid, Spain.
出版信息
Antimicrob Agents Chemother. 2010 Apr;54(4):1647-9. doi: 10.1128/AAC.01399-09. Epub 2010 Jan 25.
Abstract
The influence of ribavirin trough concentrations (RBV C(trough)) on the risk of hepatitis C virus (HCV) relapse was retrospectively analyzed in 99 HIV-HCV-coinfected patients who achieved end-of-treatment response with pegylated alpha interferon plus weight-based RBV. The independent predictors (odds ratio [OR] [95% confidence interval (CI)]) of HCV relapse were RBV plasma C(trough) of <2.5 microg/ml (4.5 [1.3 to 15.5]), baseline serum HCV RNA (2.5 [1.2 to 5.1]), and HCV genotype 1 or 4 (13.3 [2.6 to 66.7]). Monitoring of RBV C(trough) may permit early adjustment of RBV dosage to avoid HCV relapse.
摘要
回顾性分析了 99 例接受聚乙二醇干扰素α联合基于体重的利巴韦林治疗并获得治疗结束时应答的 HIV-HCV 共感染患者，分析利巴韦林谷浓度（RBV C(trough))对丙型肝炎病毒（HCV）复发风险的影响。HCV 复发的独立预测因子（比值比[OR] [95%置信区间（CI)]）为 RBV 血浆 C(trough) <2.5μg/ml（4.5 [1.3 至 15.5]）、基线血清 HCV RNA（2.5 [1.2 至 5.1]）和 HCV 基因型 1 或 4（13.3 [2.6 至 66.7]）。监测 RBV C(trough) 可能有助于早期调整 RBV 剂量以避免 HCV 复发。
相似文献
1
Plasma ribavirin trough concentrations at week 4 predict hepatitis C virus (HCV) relapse in HIV-HCV-coinfected patients treated for chronic hepatitis C.
Antimicrob Agents Chemother. 2010 Apr;54(4):1647-9. doi: 10.1128/AAC.01399-09. Epub 2010 Jan 25.
2
Baseline serum hepatitis C virus (HCV) RNA level and response at week 4 are the best predictors of relapse after treatment with pegylated interferon plus ribavirin in HIV/HCV-coinfected patients.
J Acquir Immune Defic Syndr. 2007 Aug 1;45(4):439-44. doi: 10.1097/QAI.0b013e318061b5d9.
3
Rate and predictors of success in the retreatment of chronic hepatitis C virus in HIV/hepatitis C Virus coinfected patients with prior nonresponse or relapse.
J Acquir Immune Defic Syndr. 2010 Mar;53(3):364-8. doi: 10.1097/QAI.0b013e3181bd5ce1.
4
Comparison of high ribavirin induction versus standard ribavirin dosing, plus peginterferon-α for the treatment of chronic hepatitis C in HIV-infected patients: the PERICO trial.
J Infect Dis. 2012 Sep 15;206(6):961-8. doi: 10.1093/infdis/jis449. Epub 2012 Jul 17.
5
Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin.
Antivir Ther. 2004 Aug;9(4):505-9.
6
Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir.
Antivir Ther. 2008;13(3):429-37.
7
Low Efficacy of Pegylated Interferon plus Ribavirin plus Nitazoxanide for HCV Genotype 4 and HIV Coinfection.
PLoS One. 2015 Dec 7;10(12):e0143492. doi: 10.1371/journal.pone.0143492. eCollection 2015.
8
Response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C due to genotype 4.
J Viral Hepat. 2008 Oct;15(10):710-5. doi: 10.1111/j.1365-2893.2008.01015.x. Epub 2008 Jul 10.
9
10
Ribavirin Concentrations Do Not Predict Sustained Virological Response in HIV/HCV-Coinfected Patients Treated with Ribavirin and Pegylated Interferon in the Swiss HIV Cohort Study.
PLoS One. 2015 Jul 28;10(7):e0133879. doi: 10.1371/journal.pone.0133879. eCollection 2015.
引用本文的文献
1
Ribavirin Concentrations Do Not Predict Sustained Virological Response in HIV/HCV-Coinfected Patients Treated with Ribavirin and Pegylated Interferon in the Swiss HIV Cohort Study.
PLoS One. 2015 Jul 28;10(7):e0133879. doi: 10.1371/journal.pone.0133879. eCollection 2015.
2
A pharmacological profile of ribavirin and monitoring of its plasma concentration in chronic hepatitis C infection.
J Clin Exp Hepatol. 2012 Mar;2(1):42-54. doi: 10.1016/S0973-6883(12)60090-5. Epub 2012 Apr 12.
3
In Vitro Assessment of Re-treatment Options for Patients with Hepatitis C Virus Genotype 1b Infection Resistant to Daclatasvir Plus Asunaprevir.
Infect Dis Ther. 2014 Dec 17;4(1):137-44. doi: 10.1007/s40121-014-0052-8.
4
[Not Available].
Can J Infect Dis Med Microbiol. 2014 Spring;25(1):39-62. doi: 10.1155/2014/921314.
5
CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core: Canadian guidelines for management and treatment of HIV/hepatitis C coinfection in adults.
Can J Infect Dis Med Microbiol. 2013 Winter;24(4):217-38. doi: 10.1155/2013/781410.
6
Multiplex liquid chromatography-tandem mass spectrometry assay for simultaneous therapeutic drug monitoring of ribavirin, boceprevir, and telaprevir.
Antimicrob Agents Chemother. 2013 Jul;57(7):3147-58. doi: 10.1128/AAC.00281-13. Epub 2013 Apr 29.
7
Role of the Pharmacist in Caring for Patients with HIV/AIDS: Clinical Practice Guidelines.
Can J Hosp Pharm. 2012 Mar;65(2):125-45. doi: 10.4212/cjhp.v65i2.1120.
本文引用的文献
1
The utility of therapeutic drug monitoring for ribavirin in patients with chronic hepatitis C--a critical review.
Ann Pharmacother. 2009 Dec;43(12):2044-63. doi: 10.1345/aph.1M225. Epub 2009 Nov 17.
2
Ribavirin plasma concentration predicts sustained virological response to peginterferon Alfa 2a plus ribavirin in previously treated HCV-HIV-coinfected patients.
J Acquir Immune Defic Syndr. 2009 Nov 1;52(3):428-30. doi: 10.1097/QAI.0b013e3181b62858.
3
Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.
N Engl J Med. 2009 Apr 30;360(18):1839-50. doi: 10.1056/NEJMoa0807650.
4
Usefulness of monitoring ribavirin plasma concentrations to improve treatment response in patients with chronic hepatitis C.
J Antimicrob Chemother. 2008 Dec;62(6):1174-80. doi: 10.1093/jac/dkn421. Epub 2008 Oct 17.
5
Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone.
J Antimicrob Chemother. 2008 Dec;62(6):1365-73. doi: 10.1093/jac/dkn420. Epub 2008 Oct 13.
6
Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir.
Antivir Ther. 2008;13(3):429-37.
7
The use of trough ribavirin concentration to predict sustained virological response and haematological toxicity in HIV/HCV-co-infected patients treated with ribavirin and pegylated interferon.
J Antimicrob Chemother. 2008 Apr;61(4):919-24. doi: 10.1093/jac/dkn013. Epub 2008 Jan 31.
8
Rapid virologic response: a new milestone in the management of chronic hepatitis C.
Clin Infect Dis. 2008 Jan 1;46(1):78-84. doi: 10.1086/523585.
9
Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial.
Hepatology. 2008 Jan;47(1):43-50. doi: 10.1002/hep.22061.
10
Measurement of ribavirin plasma concentrations by high-performance liquid chromatography using a novel solid-phase extraction method in patients treated for chronic hepatitis C.
Ther Drug Monit. 2007 Dec;29(6):802-6. doi: 10.1097/FTD.0b013e31815bddf3.
Zotero 插件